30 September 2026 in ACTAS PERUANAS DE ANESTESIOLOGIA
Introduction: Perioperative management of antithrombotic therapy remains a major clinical challenge, given the balance between bleeding risk and the thromboembolic risk of its interruption. This study analyzed perioperative thromboembolic complications following temporary interruption and/or delayed resumption of antithrombotic therapy, and compared the management decisions made with current recommendations. Case presentation: Five consecutive cases occurring over a five-year period were retrospectively evaluated: one acute myocardial infarction and four ischemic strokes associated with the perioperative interruption of clopidogrel, ticagrelor, acetylsalicylic acid, or apixaban before procedures with varying bleeding risk. Discussion: For low-risk procedures, such as cataract surgery or conventional dental extractions, current evidence does not support routine discontinuation of antiplatelet therapy, given the low bleeding risk and the potential increase in thromboembolic events. In procedures with higher bleeding risk, such as transurethral bladder resection or vitreoretinal surgery, the therapeutic decision should be individualized and antithrombotic therapy resumed promptly once hemostasis is ensured. In exceptional cases with both high thrombotic and bleeding risk and non-deferrable surgery, bridging therapy with intravenous antiplatelet agents may be considered. Conclusion: Three of the five complications occurred before surgery, associated with the anesthesiologist's decision to discontinue treatment. Correct application of current recommendations and multidisciplinary coordination are key to minimizing perioperative complications. A prospective observational study would have an impact on future clinical practice.